[go: up one dir, main page]

MX2022015157A - Anticuerpos para tigit. - Google Patents

Anticuerpos para tigit.

Info

Publication number
MX2022015157A
MX2022015157A MX2022015157A MX2022015157A MX2022015157A MX 2022015157 A MX2022015157 A MX 2022015157A MX 2022015157 A MX2022015157 A MX 2022015157A MX 2022015157 A MX2022015157 A MX 2022015157A MX 2022015157 A MX2022015157 A MX 2022015157A
Authority
MX
Mexico
Prior art keywords
antibodies
tigit
cells
inhibiting
cancer
Prior art date
Application number
MX2022015157A
Other languages
English (en)
Inventor
John Lippincott
Kelsey Sivick Gauthier
Nigel Pelham Clinton Walker
Xiaoning Zhao
Original Assignee
Arcus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcus Biosciences Inc filed Critical Arcus Biosciences Inc
Publication of MX2022015157A publication Critical patent/MX2022015157A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente descripción proporciona anticuerpos que se unen específicamente a TIGIT. Los anticuerpos tienen la capacidad de activación sustancial de células T y células destructoras naturales al inhibir la unión de TIGIT a CD155. Los anticuerpos pueden usarse para el tratamiento del cáncer y enfermedades infecciosas, entre otras aplicaciones.
MX2022015157A 2020-06-02 2021-06-01 Anticuerpos para tigit. MX2022015157A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063033609P 2020-06-02 2020-06-02
PCT/US2021/035268 WO2021247591A1 (en) 2020-06-02 2021-06-01 Antibodies to tigit

Publications (1)

Publication Number Publication Date
MX2022015157A true MX2022015157A (es) 2023-01-16

Family

ID=76601830

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015157A MX2022015157A (es) 2020-06-02 2021-06-01 Anticuerpos para tigit.

Country Status (19)

Country Link
US (2) US11820824B2 (es)
EP (1) EP4157875A1 (es)
JP (2) JP7776448B2 (es)
KR (1) KR20230019152A (es)
CN (1) CN115698068A (es)
AR (1) AR122493A1 (es)
AU (1) AU2021284273A1 (es)
BR (1) BR112022024221A2 (es)
CA (1) CA3176246A1 (es)
CL (1) CL2022003397A1 (es)
CO (1) CO2022017348A2 (es)
CR (1) CR20220611A (es)
DO (1) DOP2022000272A (es)
IL (1) IL298111A (es)
MX (1) MX2022015157A (es)
PE (1) PE20231078A1 (es)
PH (1) PH12022553257A1 (es)
TW (1) TW202210514A (es)
WO (1) WO2021247591A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220611A (es) 2020-06-02 2023-06-07 Arcus Biosciences Inc Anticuerpos anti-tigit
IL312348A (en) 2021-10-29 2024-06-01 Arcus Biosciences Inc HIF-2ALPHA inhibitors and methods of using it
WO2023105281A1 (en) * 2021-12-11 2023-06-15 Fundaciò Privada Institut De Recerca De La Sida-Caixa Soluble tigit recombinant proteins
EP4554680A1 (en) 2022-07-15 2025-05-21 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
US20260028336A1 (en) 2022-07-20 2026-01-29 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
JP2025531079A (ja) 2022-09-14 2025-09-19 アーカス バイオサイエンシズ インコーポレイティド エトルマデナントの分散体
WO2024081385A1 (en) 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
EP4604920A1 (en) 2022-10-20 2025-08-27 Arcus Biosciences, Inc. Lyophilized formulations of cd73 compounds
CN121114441A (zh) * 2023-04-23 2025-12-12 郑州大学 抗肿瘤相关抗原pten自身抗体在制备afp阴性肝癌诊断产品中的应用
WO2024233360A1 (en) 2023-05-05 2024-11-14 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024243502A1 (en) 2023-05-25 2024-11-28 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
AU2024281414A1 (en) 2023-06-02 2025-12-11 Arcus Biosciences, Inc. Biomarkers for predicting cancer treatment efficacy
WO2025002151A1 (zh) * 2023-06-27 2025-01-02 正大天晴药业集团股份有限公司 抗tigit抗体及其应用
WO2025011443A1 (en) * 2023-07-07 2025-01-16 D3 Bio (Wuxi) Co., Ltd. Combination therapies for the treatment of cancer
WO2025038857A1 (en) 2023-08-16 2025-02-20 Arcus Biosciences, Inc. TETRALINS TARGETING MUTANT HIF-2α
WO2025054339A1 (en) 2023-09-08 2025-03-13 Arcus Biosciences, Inc. Triazolopyridine compounds as inhibitors of kit
WO2025072330A1 (en) 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Kit inhibitor compounds and methods of use thereof
TW202517260A (zh) 2023-10-06 2025-05-01 美商阿克思生物科學有限公司 Ｃｂｌ—ｂ抑制劑及其使用方法
TW202523302A (zh) 2023-11-02 2025-06-16 美商阿克思生物科學有限公司 噻唑化合物及其使用方法
WO2025137370A1 (en) 2023-12-20 2025-06-26 Arcus Biosciences, Inc. Salt forms of an axl inhibitor
WO2025193759A1 (en) 2024-03-12 2025-09-18 Gilead Sciences, Inc. Solid forms of an azolopyrimidine compound
WO2025235493A1 (en) 2024-05-07 2025-11-13 Arcus Biosciences, Inc. Casdatifan for use in the treatment of cancer
WO2026006759A1 (en) 2024-06-28 2026-01-02 Arcus Biosciences, Inc. Pharmaceutical compositions, dosage forms, and methods of making and using same

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ATE420178T1 (de) 1992-08-21 2009-01-15 Univ Bruxelles Immunoglobuline ohne leichtkette
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
WO1994029457A2 (en) 1993-06-09 1994-12-22 Unilever N.V. Process for producing fusion proteins comprising scfv fragments by a transformed mould
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US7473423B2 (en) 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
WO1997043416A1 (en) 1996-05-10 1997-11-20 Biogen, Inc. Common gamma chain blocking agents
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
DE60036082T2 (de) 1999-02-05 2008-06-12 Samsung Electronics Co., Ltd., Suwon Verfahren und vorrichtung zur wiederauffindung von texturbildern
IL158969A0 (en) 2001-06-01 2004-05-12 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
JP2005535290A (ja) 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
EP2277532A1 (en) 2002-09-11 2011-01-26 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
CA2602777C (en) 2005-03-25 2018-12-11 Tolerrx, Inc. Gitr binding molecules and uses therefor
JP5004154B2 (ja) 2005-04-06 2012-08-22 一般財団法人化学及血清療法研究所 組換え抗ボツリヌス神経毒素抗体
JP2008544746A (ja) 2005-05-12 2008-12-11 ザイモジェネティクス， インコーポレイテッド 免疫応答を調節するための組成物および方法
US7736647B2 (en) 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP2004682A2 (en) 2006-04-13 2008-12-24 Zymogenetics, Inc. Tetramerizing polypeptides and methods of use
FI20075059A0 (fi) 2007-01-29 2007-01-29 Valtion Teknillinen Allergeeniä sitovat monoklonaaliset IgE-vasta-aineet ja hypoallergeenit:tyypin l lgE:n ja allergeenin immunokompleksivuorovaikutus
AU2008211807B2 (en) 2007-01-29 2013-09-19 Valtion Teknillinen Tutkimuskeskus Method for producing novel IgE based reagents
US8163279B2 (en) 2007-04-13 2012-04-24 Stemline Therapeutics, Inc. IL3Rα antibody conjugates and uses thereof
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009064944A2 (en) 2007-11-16 2009-05-22 Nuvelo, Inc. Antibodies to lrp6
WO2009073163A1 (en) 2007-12-03 2009-06-11 American Type Culture Collection (Atcc) Avian influenza antibodies, compositions, and methods thereof
HUE036780T2 (hu) 2008-04-09 2018-07-30 Genentech Inc Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére
US8410251B2 (en) 2008-06-20 2013-04-02 National University Corporation Okayama University Antibody against calcified globule and use of the same
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US8183346B2 (en) 2008-12-05 2012-05-22 Eli Lilly And Company Anti-ferroportin 1 monoclonal antibodies and uses thereof
EP4331604B9 (en) 2008-12-09 2025-07-23 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
DK2419447T3 (en) 2009-04-17 2017-09-25 Immunas Pharma Inc ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMER AND USE THEREOF
ES2624835T3 (es) 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
US9476887B2 (en) 2009-08-18 2016-10-25 National Research Council Of Canada Screening of protein candidates
CA2772613C (en) 2009-09-03 2020-03-10 Schering Corporation Anti-gitr antibodies
EP2488867B1 (en) 2009-10-14 2020-09-30 Janssen Biotech, Inc. Methods of affinity maturing antibodies
HUE044179T2 (hu) 2009-12-10 2019-10-28 Hoffmann La Roche Elsõsorban humán CSF1R extracelluláris domén 4-et megkötõ antitestek és ezek alkalmazása
DK2539366T3 (en) 2010-02-26 2018-02-05 Bioarctic Neuroscience Ab PROTOFIBRIL-BINDING ANTIBODIES AND THEIR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR PARKINSON'S DISEASE, DEMENS WITH LEWY BODY AND OTHER ALPHA SYNUCLEINOPATHIES
SG10201604336VA (en) 2010-03-04 2016-07-28 Macrogenics Inc Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
EP2542588A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
FR2959416B1 (fr) 2010-05-03 2012-06-22 Monoclonal Antibodies Therapeutics Mat Biopharma Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
NZ603193A (en) 2010-05-04 2014-07-25 Five Prime Therapeutics Inc Antibodies that bind csf1r
CN103168048B (zh) 2010-06-09 2017-02-15 酶原遗传学有限公司 二聚vstm3融合蛋白和相关的组合物和方法
JP2012021943A (ja) 2010-07-16 2012-02-02 National Cancer Center 子宮体がんの検査方法、子宮体がんの検査薬、並びに子宮体がん抗原に対する抗体
US20120039916A1 (en) 2010-08-13 2012-02-16 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
MY177065A (en) 2010-09-09 2020-09-03 Pfizer 4-1bb binding molecules
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
BR112013010544A2 (pt) 2010-10-29 2016-08-02 Immunogen Inc moléculas de ligação ao egfr e imunoconjugados das mesmas
WO2012078793A2 (en) 2010-12-07 2012-06-14 Board Of Regents, The University Of Texas System Methods and compositions related to tazarotene-induced gene 1 (tig1)
CA2820885A1 (en) 2010-12-08 2012-09-07 Stem Centrx, Inc. Novel modulators and methods of use
US20120231023A1 (en) 2011-03-08 2012-09-13 Baylor Research Institute Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells
WO2012129227A1 (en) 2011-03-22 2012-09-27 Baylor Research Institute Dendritic cells (dcs) targeting for tuberculosis (tb) vaccine
TW201300418A (zh) 2011-03-25 2013-01-01 Baylor Res Inst 用於抗ｃ型肝炎病毒免疫之組合物及方法
PT2699264T (pt) 2011-04-20 2018-05-23 Medimmune Llc Anticorpos e outras moléculas que ligam b7-h1 e pd-1
US9127061B2 (en) 2011-06-24 2015-09-08 Perseus Proteomics Inc. Anti-human P-cadherin (CDH3) recombinant antibody
ES2808152T3 (es) 2011-11-28 2021-02-25 Merck Patent Gmbh Anticuerpos anti-PD-L1 y usos de los mismos
BR112014012624A2 (pt) 2011-12-15 2018-10-09 F Hoffmann-La Roche Ag anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
CA2861122A1 (en) 2012-02-06 2013-08-15 Genentech, Inc. Compositions and methods for using csf1r inhibitors
JP6187255B2 (ja) 2012-02-21 2017-08-30 東レ株式会社 癌の治療及び／又は予防用医薬組成物
JP6187256B2 (ja) 2012-02-21 2017-08-30 東レ株式会社 癌の治療及び／又は予防用医薬組成物
PH12020500604A1 (en) 2012-02-24 2023-06-14 Abbvie Stemcentrx Llc Anti sez6 antibodies and methods of use
JP6089047B2 (ja) 2012-02-24 2017-03-01 アッヴィ・ステムセントルクス・エル・エル・シー Ｄｌｌ３モジュレーター及び使用方法
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2013147169A1 (ja) 2012-03-30 2013-10-03 東レ株式会社 肝臓癌の治療及び／又は予防用医薬組成物
PL2832366T3 (pl) 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego
EP2834271B1 (en) 2012-04-03 2019-01-16 NovelMed Therapeutics, Inc. Humanized and chimeric anti-factor bb antibodies and uses thereof
AU2012376421A1 (en) 2012-04-04 2014-11-13 Perseus Proteomics Inc. Drug conjugate comprising anti-cdh3 (p-cadherin) antibody
HK1208233A1 (en) 2012-05-11 2016-02-26 戊瑞治疗有限公司 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CA2871116A1 (en) 2012-05-14 2013-11-21 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2858673A4 (en) 2012-06-06 2016-06-22 Oncomed Pharm Inc BONDING AGENT FOR MODULATING THE HIPPO PATH AND USES THEREOF
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
HK1212214A1 (en) 2012-08-31 2016-06-10 戊瑞治疗有限公司 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CN104968364A (zh) 2012-12-03 2015-10-07 百时美施贵宝公司 强化免疫调变性Fc融合蛋白的抗癌活性
JP2016502554A (ja) 2012-12-04 2016-01-28 オンコメッド ファーマシューティカルズ インコーポレイテッド 結合物質を用いた免疫療法
PL3594240T3 (pl) 2013-05-20 2024-04-02 F. Hoffmann-La Roche Ag Przeciwciała przeciwko receptorowi transferyny i sposoby ich zastosowania
WO2014190305A2 (en) 2013-05-24 2014-11-27 Biogen Idec Ma Inc. Anti-gpiib/iiia antibodies or uses thereof
TW201536811A (zh) 2013-05-31 2015-10-01 Biogen Idec Inc 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途
KR20160030936A (ko) 2013-07-16 2016-03-21 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
JP2015066079A (ja) 2013-09-27 2015-04-13 オリンパス株式会社 超音波処置具、及び手術システム
EP3192812B1 (en) 2013-12-17 2020-05-27 Genentech, Inc. Anti-cd3 antibodies and methods of use
AU2014370404A1 (en) 2013-12-24 2016-07-07 Novelmed Therapeutics, Inc. Compositions and methods of treating ocular diseases
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015133882A1 (ko) 2014-03-07 2015-09-11 사회복지법인 삼성생명공익재단 ScFv 항체 라이브러리, 이의 제조방법 및 이를 이용한 ScFv 항체 스크리닝 방법
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
KR20160146747A (ko) 2014-03-31 2016-12-21 제넨테크, 인크. 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
MA40437A (fr) 2014-07-16 2017-05-24 Hoffmann La Roche Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
JP6670297B2 (ja) 2014-08-07 2020-03-18 メモリアル スローン ケタリング キャンサー センター 抗セラミド抗体
SG11201701161QA (en) 2014-08-19 2017-03-30 Merck Sharp & Dohme Anti-tigit antibodies
WO2016073282A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
US11008403B2 (en) 2014-11-19 2021-05-18 Genentech, Inc. Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
EP3221362B1 (en) 2014-11-19 2019-07-24 F.Hoffmann-La Roche Ag Anti-transferrin receptor antibodies and methods of use
MA40662B1 (fr) 2014-12-23 2020-12-31 Bristol Myers Squibb Co Anticorps contre tigit
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
NZ739750A (en) 2015-09-25 2019-11-29 Genentech Inc Anti-tigit antibodies and methods of use
PT3356413T (pt) 2015-10-01 2022-04-04 Potenza Therapeutics Inc Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas
DK3399984T3 (da) 2016-01-08 2023-11-13 Arcus Biosciences Inc Modulatorer af 5'-nukleotidase, ecto og anvendelsen deraf
BR112018067458A2 (pt) * 2016-03-04 2019-01-02 Abmuno Therapeutics Llc anticorpos para tigit
KR20230145510A (ko) 2016-08-17 2023-10-17 컴퓨젠 엘티디. 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
EP3518934A4 (en) 2016-10-03 2020-06-24 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
CN110022881B (zh) 2016-11-18 2023-05-02 艾库斯生物科学有限公司 Cd73介导的免疫抑制的抑制剂
CA3047600A1 (en) 2017-01-20 2018-07-26 Arcus Biosciences, Inc. Azolopyrimidine for the treatment of cancer-related disorders
MY207687A (en) * 2017-02-27 2025-03-12 Shattuck Labs Inc Tigit- and light-based chimeric proteins
SG11201907278VA (en) 2017-02-28 2019-09-27 Seattle Genetics Inc Anti-tigit antibodies
MA50661A (fr) * 2017-05-02 2020-08-05 Merck Sharp & Dohme Formulations stables d'anticorps anti-tigit seuls et en association avec des anticorps du récepteur de mort programmée 1 (pd-1) et leurs procédés d'utilisation
JP7295034B2 (ja) 2017-05-05 2023-06-20 アーカス バイオサイエンシズ インコーポレイティド 癌関連障害の治療のためのキナゾリン－ピリジン誘導体
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019023504A1 (en) 2017-07-27 2019-01-31 Iteos Therapeutics Sa ANTI-TIGIT ANTIBODIES
TWI816729B (zh) 2017-12-30 2023-10-01 英屬開曼群島商百濟神州有限公司 抗tigit抗體及其作為治療和診斷的用途
SG11202004521QA (en) 2018-02-06 2020-06-29 I Mab Biopharma Us Ltd Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
SG11202100746WA (en) 2018-07-25 2021-03-30 Innovent Biologics Suzhou Co Ltd Anti-tigit antibody and use thereof
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
CN109384846B (zh) * 2018-09-25 2020-03-03 合肥瑞达免疫药物研究所有限公司 能够结合tigit的抗体或其抗原结合片段及用途
CN111196852A (zh) 2018-11-16 2020-05-26 四川科伦博泰生物医药股份有限公司 抗tigit抗体及其用途
ES3034676T3 (en) 2018-11-16 2025-08-21 Arcus Biosciences Inc Inhibitors of arg1 and/or arg2
CA3125800A1 (en) 2019-01-07 2020-07-16 iTeos Belgium SA Anti-tigit antibodies
CA3142712A1 (en) 2019-06-04 2020-12-10 Arcus Biosciences, Inc. 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds
MX2021013850A (es) 2019-06-13 2022-01-07 Green Cross Corp Anticuerpo contra tigit y uso del mismo.
AU2020314129A1 (en) 2019-07-15 2022-02-24 Shanghai Junshi Biosciences Co., Ltd. Anti-tigit antibodies and application thereof
CR20220611A (es) 2020-06-02 2023-06-07 Arcus Biosciences Inc Anticuerpos anti-tigit

Also Published As

Publication number Publication date
CN115698068A (zh) 2023-02-03
CO2022017348A2 (es) 2023-02-16
PE20231078A1 (es) 2023-07-17
JP2025172086A (ja) 2025-11-20
JP2023528036A (ja) 2023-07-03
TW202210514A (zh) 2022-03-16
EP4157875A1 (en) 2023-04-05
CA3176246A1 (en) 2021-12-09
US20220064294A1 (en) 2022-03-03
BR112022024221A2 (pt) 2022-12-20
JP7776448B2 (ja) 2025-11-26
AU2021284273A1 (en) 2022-12-15
KR20230019152A (ko) 2023-02-07
US20240182570A1 (en) 2024-06-06
DOP2022000272A (es) 2023-01-15
US11820824B2 (en) 2023-11-21
US12415854B2 (en) 2025-09-16
AR122493A1 (es) 2022-09-14
WO2021247591A1 (en) 2021-12-09
CR20220611A (es) 2023-06-07
IL298111A (en) 2023-01-01
PH12022553257A1 (en) 2024-02-19
CL2022003397A1 (es) 2023-07-28

Similar Documents

Publication Publication Date Title
MX2022015157A (es) Anticuerpos para tigit.
BR112018067458A2 (pt) anticorpos para tigit
PE20210289A1 (es) Anti-cd25 para el agotamiento de celulas tumorales especificas
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
CL2022003077A1 (es) Proteínas que se unen a nkg2d, cd16 y clec12a
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
CO2017011486A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
MX2019008989A (es) Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la artritis psoriasica activa.
AR090585A1 (es) Anticuerpos anti-hla-b*27 y usos de estos
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
CU20210096A7 (es) Moléculas de unión a cd19
MX2019009377A (es) Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
EA201790719A1 (ru) Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
CO2019012118A2 (es) Anticuerpo anti-pd-l1 y uso del mismo
PE20200618A1 (es) ANTICUERPOS ANTI-GARP-TGF-Beta1
UY36561A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CL2022003638A1 (es) Anticuerpos que se unen a cd3
CL2016002678A1 (es) “compuestos derivados de heteroarilo, ligantes d1; composición farmacéutica que los comprende; útiles en el tratamiento de enfermedades del snc, autoinmune, metabólicas, entre otras”. pct
MX2023009100A (es) Agentes aglutinantes y métodos para usar los mismos.
CO2024006215A2 (es) Anticuerpos pd-1 diseñados por ingeniería y usos de estos
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
CL2025000343A1 (es) Proteínas de unión a nkg2d, cd16 y ceacam5.
CL2020002339A1 (es) Anti–cd25 para el agotamiento de células específicas de tumores
EA201891989A1 (ru) Антитела к tigit
AR099798A1 (es) Métodos y composiciones de anticuerpos para el tratamiento de tumores